EXACT SCIENCES COREXACT SCIENCES COREXACT SCIENCES COR

EXACT SCIENCES COR

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
−0.43CHF
Revenue estimate
‪565.95 M‬CHF
Market capitalization
‪9.95 B‬CHF
−0.956CHF
‪−171.88 M‬CHF
‪2.10 B‬CHF
‪181.94 M‬
Beta (1Y)
1.79

About Exact Sciences Corporation

CEO
Kevin T. Conroy
Headquarters
Madison
Employees (FY)
‪6.6 K‬
Founded
1995
FIGI
BBG00LVDBGJ2
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of EXK is 69.112 CHF — it has decreased by 17.52% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange EXACT SCIENCES COR stocks are traded under the ticker EXK.
EXACT SCIENCES COR is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
EXK stock is 21.24% volatile and has beta coefficient of 1.79. Check out the list of the most volatile stocks — is EXACT SCIENCES COR there?
EXACT SCIENCES COR revenue for the last quarter amounts to ‪575.24 M‬ CHF despite the estimated figure of ‪564.67 M‬ CHF. In the next quarter revenue is expected to reach ‪537.86 M‬ CHF.
Yes, you can track EXACT SCIENCES COR financials in yearly and quarterly reports right on TradingView.
EXK net income for the last quarter is ‪−41.90 M‬ CHF, while the quarter before that showed ‪726.91 K‬ CHF of net income which accounts for ‪−5.86 K‬% change. Track more EXACT SCIENCES COR financial stats to get the full picture.
Today EXACT SCIENCES COR has the market capitalization of ‪10.05 B‬, it has decreased by 7.20% over the last week.
No, EXK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EXK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EXACT SCIENCES COR stock right from TradingView charts — choose your broker and connect to your account.
EXK reached its all-time high on Jun 19, 2023 with the price of 85.285 CHF, and its all-time low was 34.642 CHF and was reached on Jun 16, 2022.
See other stocks reaching their highest and lowest prices.
As of May 1, 2024, the company has ‪6.60 K‬ employees. See our rating of the largest employees — is EXACT SCIENCES COR on this list?
We've gathered analysts' opinions on EXACT SCIENCES COR future price: according to them, EXK price has a max estimate of 105.22 CHF and a min estimate of 60.38 CHF. Read a more detailed EXACT SCIENCES COR forecast: see what analysts think of EXACT SCIENCES COR and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EXACT SCIENCES COR EBITDA is ‪−65.23 M‬ CHF, and current EBITDA margin is −3.05%. See more stats in EXACT SCIENCES COR financial statements.